Appeals court says Hanmi product does not infringe Nexium patent


A U.S. court of appeals has affirmed a district court's ruling that Hanmi has not infringed AstraZeneca's (AZN) '504 patent.

The court determined that "the written description limits 'alkaline salt' in the '504 patent to certain specifically named salts."

Ultimately, this means the district court's ruling of noninfringement is upheld.

AZN "respectfully disagrees" and will consider a "further appeal," Reuters notes.

Full decision

From other sites
Comments (1)
  • mikegy
    , contributor
    Comments (2) | Send Message
     
    Would be nice to have a cheaper alternative to daily Nexium.
    19 Dec 2013, 09:13 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs